News

New lab test may help in studying effects of Spinraza treatment

Researchers have developed a new laboratory technique for measuring levels of Spinraza (nusinersen), an approved treatment for spinal muscular atrophy (SMA), in biological fluids. The test is expected to help overcome some limitations of other approaches now in use, and may therefore aid scientists and physicians when studying the…

Jerry R. Mendell makes TIME100 Health list for pioneering research

Jerry R. Mendell, MD, has been named to the inaugural TIME100 Health list for his decades-long contributions to the treatment of neuromuscular diseases — such as spinal muscular atrophy (SMA) and Duchenne muscular dystrophy (DMD) — and the advancement of gene therapy. The global media brand’s…

Abnormal immune system activation seen in SMA fly models

A range of genetic mutations associated with spinal muscular atrophy (SMA) were linked to abnormal activation of the immune system in fly models, which a team of U.S. researchers believe could be a mechanism that contributes to neurodegeneration in the rare disease. Altogether, the evidence indicated that these…

LTFU model helps SMA families, clinicians, NBS programs: Study

A program designed to provide data and tools for people with spinal muscular atrophy (SMA) identified through newborn screening (NBS) can help families and clinicians engage with public health agencies and ensure the best possible outcomes, a study found. The Long-Term Follow-up Cares and Check Initiative (LTFU-Cares…

Brain fluid biomarkers may help distinguish SMA types, study finds

Levels of certain molecules in cerebrospinal fluid (CSF) — the liquid that surrounds the brain and spinal cord — may help researchers distinguish between different types of spinal muscular atrophy (SMA), a study suggests. The study, “Metabolomics of cerebrospinal fluid reveals candidate diagnostic biomarkers to…